Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) EPS (Basic) (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed EPS (Basic) for 11 consecutive years, with -$3.57 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 2846.15% to -$3.57 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.12 through Dec 2025, up 53.11% year-over-year, with the annual reading at -$5.02 for FY2025, 12.05% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$3.57 at Cartesian Therapeutics, down from -$1.38 in the prior quarter.
  • The five-year high for EPS (Basic) was $0.58 in Q2 2024, with the low at -$41.56 in Q4 2023.
  • Average EPS (Basic) over 5 years is -$3.29, with a median of -$0.19 recorded in 2021.
  • The sharpest move saw EPS (Basic) soared 204.55% in 2022, then crashed 138633.33% in 2023.
  • Over 5 years, EPS (Basic) stood at $0.12 in 2021, then crashed by 75.0% to $0.03 in 2022, then plummeted by 138633.33% to -$41.56 in 2023, then surged by 100.31% to $0.13 in 2024, then tumbled by 2846.15% to -$3.57 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$3.57, -$1.38, and $0.51 for Q4 2025, Q3 2025, and Q2 2025 respectively.